Comprehensive ReviewInfectious Complications in Patients With Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum of Infection, and Approaches to Prophylaxis
References (43)
- et al.
Infectious complications of chronic lymphocytic leukemia
Semin Oncol
(2006) - et al.
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: A systematic review and meta-analysis
Cancer Treat Rev
(2006) - et al.
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
Blood
(2001) - et al.
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
Blood
(2006) - et al.
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712)
Blood
(2003) - et al.
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial
Blood
(2000) - et al.
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
Blood
(2002) - et al.
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
Blood
(2003) - et al.
Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab
Clin Lymphoma Myeloma
(2006) Morrison. Management of Infectious Complications in Patients with Chronic Lymphocytic Leukemia
Hematology
(2007)
Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status
Leuk Lymphoma
(2004)
The status on immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia
Cancer
(2006)
Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia and multiple myeloma
Blood
(1996)
Infectious and immunosuppressive complications of purine analog therapy
J Clin Oncol
(1995)
Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup study Cancer and Leukemia Group B 9011
J Clin Oncol
(2001)
Infections in patients with chronic lymphocytic leukemia treated with fludarabine
Ann Intern Med
(1998)
Disease activity and pretreatment, rather than hypogammaglobulinemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukemia
Br J Haematol
(2003)
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
J Clin Oncol
(2007)
Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL) Polish multicentre study
Leuk Lymphoma
(2004)
Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network
J Clin Oncol
(2003)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
J Clin Oncol
(2005)
Cited by (104)
Vaccinations in patients with chronic lymphocytic leukemia
2024, Seminars in HematologyCan Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?
2021, Hematology/Oncology Clinics of North AmericaTargeting FcRn for immunomodulation: Benefits, risks, and practical considerations
2020, Journal of Allergy and Clinical ImmunologyImmunoglobulin replacement to prevent infections in people with haematological malignancies and haematopoietic stem cell transplantation
2024, Cochrane Database of Systematic Reviews
This summary may include the discussion of investigational and/or unlabeled uses of drugs and/or devices that may not be approved by the FDA.
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1557-9190, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.
Copyright © 2009 Elsevier Inc. All rights reserved.